Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia

Ashleigh Kussman, David Shyr, Gregory Hale, Benjamin Oshrine, Aleksandra Petrovic

Research output: Contribution to journalArticlepeer-review

Abstract

Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy-induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine- or high-dose cytarabine-based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced-intensity conditioning and allogeneic transplant before hematologic recovery. Long-term disease control was achieved in five, with one transplant-related mortality, suggesting the feasibility of this approach.

Original languageEnglish (US)
Article numbere27481
JournalPediatric Blood and Cancer
Volume66
Issue number1
DOIs
StatePublished - Jan 2019
Externally publishedYes

Keywords

  • acute myeloid leukemia
  • hematopoietic cell transplantation
  • myelodysplasia
  • pediatrics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia'. Together they form a unique fingerprint.

Cite this